Lv4
408 积分 2021-04-15 加入
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
4天前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
12天前
已关闭
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
12天前
已完结
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC
12天前
已完结
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
14天前
已完结
Neoadjuvant chemotherapy in non-metastatic breast cancer: The surgeon's perspective
14天前
已完结
Introducing Neoadjuvant Immunotherapy for Colorectal Cancer
15天前
已完结
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
15天前
已完结
The Efficacy of PCSK9 Inhibitors in Treating Hypercholesterolemia Caused by Lorlatinib: A Report of Two Cases
15天前
已完结
Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Impact on Early Stage and Outcomes—Comprehensive Review
15天前
已完结
皖公网安备34019202002308
